Background: Leukemia cells highly express master differentiation-driving transcription factors yet paradoxically, terminal differentiation genes are epigenetically repressed. Results: The hematopoietic transcription factors RUNX1 and PU.1 cooperated to exchange corepressors for coactivators, and deficiency of RUNX1, frequent in leukemia, caused aberrant recruitment of specific corepressors instead of coactivators to PU.1. Conclusion: This mechanism explains the paradox. Significance: Inhibition of the specific corepressors restored terminal differentiation. FIGURE 9. Polycomb (EZH2 and G9a) inhibition increased differentiation and decreased proliferation of leukemia cells with wild-type RUNX1. Patientderived leukemia cell lines OCI-AML2 that contains DNMT3A, MLL, and FLT3 mutations, and OCI-AML3 that contains DNMT3A, NPM1, and NRAS mutations, were treated with specific EZH2 (Ei and Ei2) and G9a (Gi, Gi2) inhibitors from SGC (5 M added daily). A, polycomb inhibitors decreased proliferation. Cell counts were by an automated counter. DAC, DNMT1 inhibitor decitabine. B, polycomb inhibitors decreased MYC protein. Time course Western blots (WB) and densitometry graph (normalized to actin) were used. The DNMT1 inhibitor DAC also decreased MYC protein (data not shown). C, polycomb inhibitors induced morphologic differentiation (decreased nuclear/cytoplasmic ratio, nuclear margination, and segmentation). Giemsa-stained cytospin preparations on day 5 (ϫ200, Leica DMR, Leica Microsystems). Images were captured by a CRI Nuance NzMSI-FX multispectral imaging system with Nuance software version 3.0 (NuanceCRI). DAC also induced morphologic differentiation (data not shown). D, polycomb inhibitors increased expression of myeloid differentiation markers CD11b and/or CD14. Measurements were done by flow cytometry on day 7.
Gene activation requires cooperative assembly of multiprotein transcription factor-coregulator complexes. Disruption to cooperative assemblage could underlie repression of tumor suppressor genes in leukemia cells. Mechanisms of cooperation and its disruption were therefore examined for PU.1 and RUNX1, transcription factors that cooperate to activate hematopoietic differentiation genes. PU.1 is highly expressed in leukemia cells, whereas RUNX1 is frequently inactivated by mutation or translocation. Thus, coregulator interactions of Pu.1 were examined by immunoprecipitation coupled with tandem mass spectrometry/Western blot in wild-type and Runx1-deficient hematopoietic cells. In wild-type cells, the NuAT and Baf families of coactivators coimmunoprecipitated with Pu.1. Runx1 deficiency produced a striking switch to Pu.1 interaction with the Dnmt1, Sin3A, Nurd, CoRest, and B-Wich corepressor families. Corepressors of the Polycomb family, which are frequently inactivated by mutation or deletion in myeloid leukemia, did not interact with Pu.1. The most significant gene ontology association of Runx1-Pu.1 co-bound genes was with macrophages, therefore, functional consequences of altered corepressor/coactivator exchange were examined at Mcsfr, a key macrophage differentiation gene. In chromatin immunoprecipitation analyses, high level Pu.1 binding to the Mcsfr promoter was not decreased by Runx1 deficiency. However, the Pu.1-driven shift from histone repression to activation marks at this locus, and terminal macrophage differentiation, were substantially diminished. DNMT1 inhibition, but not Polycomb inhibition, in RUNX1-translocated leukemia cells induced terminal differentiation. Thus, RUNX1 and PU.1 cooperate to exchange corepressors for coactivators, and the specific corepressors recruited to PU.1 as a consequence of RUNX1 deficiency could be rational targets for leukemia differentiation therapy.
Exogenous and endogenous signals, integrated by transcription factors, are transmitted to chromatin via an interchange of multisubunit coregulator complexes (coactivators, corepressors) containing chromatin modifying enzymes (1) . The chromatin modifying enzymes create epigenetic activation marks (coactivators) or repression marks (corepressors) (1) (2) (3) (4) . This cooperative process mediates coordinated gene expression program changes that define cell fate yet the actual molecular forces that mediate it are mostly mysterious (1) . Mechanisms of cooperation and its oncogenic disruption were therefore examined for the key hematopoietic transcription factors RUNX1 and PU.1. RUNX1 is frequently inactivated by mutation or translocation in the myeloid cancers myelodysplastic syndrome and acute myeloid leukemia (AML) 3 (ϳ20% of cases) (5) (6) (7) . RUNX1 by itself is a weak activator of transcription (8 -12) , however, RUNX1 synergistically augments transcription activation by multiple hematopoietic lineage specifying transcription factors: PU.1, CEBPA, ETS1, GATA1, GATA2, FLI1, PAX5, SCL, and ERG (9 -19) . Previously, we demonstrated a mechanism determining corepressor recruitment by RUNX1 and one such partner, the macrophage-differentiation driving transcription factor PU.1: RUNX1 and PU.1 separately interacted with the corepressors SIN3A, ETO2, and HDAC2, however, when RUNX1 and PU.1 were together, the corepressors were excluded (20) . Substitution of wild-type RUNX1 in the RUNX1⅐PU.1 complex with truncated versions that initiate leukemogenesis (e.g. RUNX1-ETO), or deficiency of RUNX1, compromised corepressor exclusion; PU.1 interacted with SIN3A, ETO2, and HDAC2 again and PU.1 target genes were repressed instead of activated, accompanied by a decrease in histone activation marks (20) .
These first time observations regarding cooperation between two DNA-binding transcription factors to exclude corepressors provoked important new questions: is there exchange of corepressors for coactivators instead? Such an observation would extend the existing model in which ligand binding to nuclear receptors drives coregulator exchange (1) . If so, which of the numerous coactivators that are expressed in hematopoietic cells are specifically recruited to the RUNX1⅐PU.1 complex? Answering these questions could provide insight into leukemogenesis, because a putative method by which leukemia cells repress proliferation-terminating differentiation genes is by genetic inactivation of coactivator subunits that mediate their activation. Other questions have direct treatment implications: of the hundreds of chromatin regulators that are expressed in hematopoietic cells, the specific subset aberrantly recruited to differentiation-promoting transcription factors in leukemia cells would be logical targets for inhibition to restore terminal differentiation (21) . Because public-private efforts such as the Structural Genomics Consortium are generating chemical probes (inhibitors) specific for each of hundreds of chromatin regulators expressed in hematopoietic cells, such information could have near term practical impact via provision of a biological rationale to prioritize some inhibitors over others.
Thus, our overall purpose was to examine, in a manner that would provide insights into leukemogenesis and identify specific drugable targets for therapy, if Runx1 regulates Pu.1 corepressor/coactivator exchange.
EXPERIMENTAL PROCEDURES
Models Used for Analyses-Immunoprecipitation coupled with tandem mass spectrometry (LC-MS/MS) and Western blot were used to comprehensively evaluate Pu.1 interactions in primary hematopoietic cells from the bone marrow and spleen of wild-type and Runx1-haplosufficient mice (gift of Jim Downing laboratory (22) ), in a cell line model of Pu.1-driven macrophage differentiation (PUER) (gift of Harinder Singh laboratory (23)), and in patient-derived leukemia cells containing translocated RUNX1 (Kasumi1 cells). PUER are Pu.1 knock-out hematopoietic precursor cells that have been retrovirally transduced to express Pu.1 fused to the estrogen receptor. To generate PUER cells with stable suppression of Runx1, expression a lentiviral vector pLenti6-DEST (Invitrogen) was used to construct short hairpin (sh) RNA for Runx1. Three shRNA oligos specific to 19-bp target sequences of mouse Runx1 (shRUNX1-Clone 1, 5Ј-GGCACTCTGGTCACCGTCA-3Ј; shRunx1-Clone 2, 5Ј-GGCCATGAAGAACCAGGTA-3Ј; and shRunx1-Clone 3, 5Ј-GGCAAGAGCTTCACTCTGA-3Ј) were designed using BLOCK-iT TM RNAi Designer (Invitrogen) and synthesized in sense and antisense orientation by Integrated DNA Technology (IDT). The single strand oligos were then annealed to form double strand oligos, and subsequently ligated with pENTRY vector (Invitrogen) downstream of an RNA promoter. The ligated constructs were transformed into Escherichia coli TOPO10. Positive clones were verified by DNA sequencing. The verified clones were then recombined into pLenti6-DEST vector using the ViralPack kit (Invitrogen), resulting in pLenti6-shRunx1. The pLenti6-shRunx1 or empty vector pLenti6 (to generate PUER Control cells) were then transfected together with envelop encoding plasmid (VSVG) into the 293FT packaging cell line to produce lentivirus. The supernatant containing lentivirus was harvested at 48 h after transfection. Titers were determined on NIH3T3 cells as transducing units using serial dilutions of vector stocks with 8 g/ml of Polybrene (Sigma). PUER cells were grown in Iscove's modified Eagle's medium, without phenol red, with 10% fetal bovine serum, 5 ng/ml of mIL-3, 1 g/ml of puromycin, 55 M ␤-mercaptoethanol, 1% penicillin/streptomycin at 37°C in a humidified atmosphere with 5% CO 2 in air. The lentivirus-containing supernatant was added to the cell culture at appropriate 4 particles/cell concentration with 8 g/ml of Polybrene. Twenty-four hours after infection, 4 g/ml of blasticidin was added to the cell culture for positive clone selection. The blasticidin-resistant cells were analyzed for Runx1 by RT-qPCR and Western blot.
Cell Fractionation and Nuclear Protein Extraction-Approximately 50 million each of Runx1-haploinsufficient and wildtype littermate control bone marrow or spleen cells (pooled from multiple mice), or 100 million each of PUER and PUER shRunx1 cells, were used in the preparation. After removal of the medium, cells were transferred to 15-ml conical tubes and washed twice with 10 ml of ice-cold 1ϫ PBS that contained protease inhibitors (Sigma, A8340). Cells were resuspended in 500 l of 1ϫ hypotonic buffer containing 10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol, 10 mM PMSF, and protease inhibitors (Sigma, A8340). A total of 20 l of 10% Nonidet P-40 was added to cell suspensions to break the cell membrane. After a 5-min incubation on ice, cell suspensions were centrifuged at 344 ϫ g for 10 min. The supernatant was transferred to clean 1.5-ml Eppendorf tubes and labeled as the cytoplasmic fraction. Nuclear pellets were washed twice with ice-cold 1ϫ PBS, and resuspended in 100 l of 50 mM Tris-HCl, pH 8.0, 1 mM MgCl 2 , 10 mM PMSF, protease inhibitor mixture (Sigma, A8340) and Benzonase (Sigma, D5915, 250 units). The nuclear suspensions were incubated on ice for 90 min with vigorous vortexing every 5 min. At the end of the incubation, 500 l of protein extraction buffer containing 1.5% Nonidet P-40, 500 mM NaCl, 5 mM dithiothreitol, 10 mM PMSF, and 5 l of protease inhibitor mixture (Sigma, A8340) in 50 mM phosphate buffer, pH 7.4, were added. After a 30-min incubation on ice with vortexing every 5 min, the mixture was centrifuged at 12,396 ϫ g for 15 min. The same extraction process was repeated two more times with 300 and 200 l of extraction buffer. The supernatant containing nuclear proteins was combined and transferred to clean tubes, and the protein concentration was determined by a BCA assay.
Covalent Bound Antibody to Protein G Beads-Goat anti-Pu.1 (SCBT, sc-5949) and control goat IgG were covalently coupled to Sepharose-protein G beads using dimethylpimelimidate. Briefly, 25 mg of protein G-Sepharose CL-4B (GE Healthcare, 17-0780-01) was swelled in 1 ml of 1ϫ PBS overnight and incubated with 200 l of antibody (50 g) solution (1ϫ PBS) for 1 h at room temperature. Antibody bound protein G beads were then incubated with 1% chicken egg ovalbumin in PBS for another hour to block nonspecific binding sites. After 3 washes with 1ϫ PBS, 25 mg of dimethylpimelimidate in 1 ml of 200 mM triethanyl amine was added, and the coupling reaction proceeded at room temperature for 30 min. The reaction was repeated 2 more times with fresh addition of dimethylpimelimidate and quenched with 50 mM ethanol amine. The reacted protein G beads were washed extensively with 1ϫ PBS before immunoprecipitation.
Immunoprecipitation-Nuclear protein extracts (ϳ10 mg of protein) were transferred to tubes with antibody-bound protein G beads and rocked gently at 4°C overnight. Nonspecifically bound proteins were removed with 5 washes of 1ϫ PBS containing 1% Nonidet P-40. Immunoprecipitation products were extracted from protein G beads using Laemmli sample buffer.
Protein Identification by LC-MS/MS-Anti-Pu.1 and isotype antibody immunoprecipitation products were subjected to SDS-polyacrylamide gel electrophoresis and stained with colloidal Coomassie Blue (Gel Code Blue, Pierce Chemical). Gel slices were excised from the top to the bottom of the lane; proteins were reduced with dithiothreitol (10 mM), alkylated with iodoacetamide (55 mM), and digested in situ with trypsin. Peptides were extracted from gel pieces 3 times using 60% acetonitrile and 0.1% formic acid/water. The dried tryptic peptide mixture was redissolved in 15 l of 0.1% formic acid and 5% acetonitrile for mass spectrometric analysis. Tryptic peptide mixtures were analyzed by on-line LC-coupled tandem mass spectrometry (LC-MS/MS) on a QTOF2 mass spectrometer (Waters) using a Cap LC XE system (Waters), a 0.3 ϫ 5-mm trapping column (C18 PepMap 100, LC Packings), a reverse phase separating column (75 m ϫ 5 cm, Vydac C18), and a flow rate of 250 nl/min. Gradient LC separation was achieved with aqueous formic acid/acetonitrile solvents. The QTOF2 mass spectrometer was operated in standard MS/MS switching mode with the 4 most intense ions in each survey scan subjected to MS/MS analysis. Instrument operation and data acquisition used MassLynx version 4.1 software (Waters). Initial protein identifications from MS/MS data used the online Mascot search engine and the Swiss Protein mouse sequence database (May 2012 release, 16529 total sequences). The Swiss Protein database search parameters included the allowed 2 missed tryptic cleavage sites, precursor ion mass tolerance of 1.2 Da, fragment ion mass tolerance of 0.6 Da, protein modifications for Met oxidation, and Cys carbamidomethylation. MS/MS datasets were also analyzed by the same search engine and parameters against all mammals (May 2012 release, 36529 total sequence). A minimum Mascot ion score of 25 was used for automatically accepting all peptide MS/MS spectra. A Mascotintegrated decoy database search calculated a false discovery of Յ3.55% when searching was performed on the concatenated mgf files with an ion score cut-off of 25 and a significance threshold of p Յ 0.01. Only peptides with ion scores of Ն25 and only proteins with at least one unique peptide ranked as a top candidate (bold red in Mascot) were considered and re-imported into Progenesis software. All protein identifications including peptide sequences are listed in supplemental Tables S1 and S2. Identifications and quantifications of proteins based on only one peptide adhered to published Molecular Cellular Proteomics guidelines and were accepted with caution for the explorative phase (pathway enrichment and protein network analyses) with confirmation in additional model systems and by Western blot. Identification and quantification data are presented including spectra for each single peptide with y-and b-series labeled (supplemental Fig. S1 ).
Label Free Peptide Quantifications-The acquired spectra were loaded (Waters raw files) to Progenesis software (version 2.5, Nonlinear) for label free quantification. Profile data of the MS scans were transformed to peak lists with the Progenesis LC-MS algorithm. Peaks were then modeled in non-noisy areas to record their peak m/z value, intensity, abundance (area under the peak), and m/z width. One Pu.1 IP experiment was selected as a reference and other samples within the experiment were automatically aligned. Peaks with only one charge or more than five charges are masked at this point and excluded from further analyses. Mascot search results were imported to connect each peptide with protein identification. For quantification, all peptides (with Mascot score Ն30 and p Ͻ 0.01) of an identified protein were included and the total cumulative abundance was calculated by summing the abundances of all peptides allocated to the respective protein. To correct for experimental variation, each protein abundance was normalized to the abundance of the bait protein (Pu.1). Calculations of the protein p value (one-way analysis of variance) were then performed on the sum of the normalized abundances across all runs. Analysis of variance values of p Յ 0.05 and fold-changes of Ն2 or Յ0.5 were regarded as significant.
Pathway Enrichment Analysis and Protein Network Analysis-Protein-protein interactions were evaluated using Significance Analysis of INTeractome (SAINT). SAINT is a software package for scoring protein-protein interactions based on label free quantitative proteomics data (e.g. spectral count or peptide peak intensity) in affinity purification-mass spectrometry experiments. iProbability is calculated for each protein based on the strength of identification and the likelihood for contamination imbedded in the CRAPOME database (Contaminant Repository for Affinity Purification and Mass Spectrometry). Any protein with an average p value (AvgP) Ͼ0.5 is considered to be a significant interaction between the bait protein (Pu.1) and prey proteins (supplemental Table S4 ).
The "core analysis" function included in IPA (Ingenuity System Inc.) was used to interpret the data in the context of biological processes, pathways, and networks. All identifier types were selected because more than one type of identifier exists in our dataset (working file). Both up-and down-regulated identifiers were defined as value parameters for the analysis.
One-dimensional SDS-polyacrylamide Gel Electrophoresis and Western Blot Analysis-Immunoprecipitation products, control immunoprecipitation products, 100 g of nuclear protein extracts from wild-type/Runx1 ϩ/Ϫ murine bone marrow, wild-type/Runx1 ϩ/Ϫ murine spleen, or PUER Empty Vector/ PUER shRunx1, together with molecular weight markers, were subjected to one-dimensional SDS-polyacrylamide gel electrophoresis on precast 4 -12% NuPAGE gels (Invitrogen). After electrophoresis per the manufacturer's instructions (Invitrogen), proteins were transferred to polyvinylidene difluoride membranes (Millipore) at 35 constant voltage for 1 h using a XCell II Blot module (Invitrogen). Primary antibodies used in the study were anti-PU.1 (Cell Signaling, 2266), anti-Runx1 (SCBT, sc-101146), anti-ETO2 (SCBT, sc-28694), anti-Sin3A (SCBT, sc-994), anti-HDAC1 (SCBT, sc-7872), anti-HDAC2 (SCBT, sc-7899), anti-SMARCA4 (Brg1, Cell Signaling, 3508S), anti-CHD4 (NB100 -57521, Novus Biologicals), anti-LSD1 (sc-271720, SCBT), anti-DNMT1 (ab92453, ABCAM), anti-NCOA5 (A300 -790A, Bethyl Laboratories), anti-RUVB1 (3918-1, Epitomics), anti-RUVB2 (2889 -, Epitomics), anti-RBBP4 (ab38135, ABCAM), anti-SMARCA5 (05-698, Millipore), anti-MBD2 (sc-9397, SCBT), anti-PHB2 (sc-133094, SCBT), and anti-␤-actin peroxidase (Sigma, A3854). Secondary antibodies, anti-rabbit (GE Healthcare, NA934) and antimouse (GE Healthcare, NXA931), were used at 1:10,000 and 1:5,000 dilutions, respectively.
Chromatin Immunoprecipitation (ChIP) Assays-5 ϫ 10 6 cells were cross-linked with 1% formaldehyde for 10 min at room temperature and subsequently harvested and washed with ice-cold PBS. Cross-linked cells were lysed with 250 l of SDS lysis buffer with fresh protease inhibitors (1 mM PMSF, 1 g/ml of aprotinin, and 1 g/ml of pepstatin A), followed by sonication for a total of 10 min at 20-s intervals using a Fisher Scientific Sonic Dismembrator 550 equipped with microtip (setting 3; 10% input). Gel electrophoresis was used to confirm that fragments were ϳ200 bp in size. 50 l of sonicated chromatin lysates were saved as input. The remaining lysates were diluted to 900 l with 1% Nonidet P-40, 5 mM dithiothreitol, 10 mM PMSF, and 5 l of protease inhibitor mixture (Sigma, A8340) in 1ϫ PBS, pH 7.4. The diluted lysates were equally divided and used for immunoprecipitations with dimethyl-H3K4 (Pierce, PA5-17174), dimethyl-H3K9 (Cell Signaling, 4658) antibodies, Pu.1 (Cell Signaling, 2266), Runx1 (SCBT, DW71), and normal mouse or rabbit IgG as control. Lysates were incubated with antibodies overnight at 4°C with rotation. Immunoprecipitates were then collected with salmon sperm DNA/protein A-agarose slurry beads (Millipore, catalog number 16-157C). After extensive wash of the protein-DNA bound beads, protein/DNA cross-links were reversed by incubating at 65°C for 4 h, followed by incubation with 0.05 g/ml of protease K for 1 h at 45°C. DNA was recovered by phenol/chloroform extraction and ethanol precipitation. ChIP DNA containing gene promoters associated with Pu.1, Runx1, H3K4me2, and H3K9me2 were analyzed by RT-qPCR. Primers targeting the proximal promoters of macrophage-colony stimulating factor receptor (Mcsfr/Csf1r), and granulocyte-colony stimulating factor receptor (Gcsfr/Csfr3) were: Mcsfr, forward 5Ј-GGAGT-GATTTGTCTACAGG-3Ј, reverse 5Ј-ATCTGCCCTTAAGG-CAGAAGG-3Ј (Mcsfr promoter from Ϫ260 to Ϫ105); Gcsfr, forward 5Ј-TAAGACCCCTGAGGCAGGAA-3Ј, reverse 5Ј-CTAGCCCCGTCGTTAATGACA-3Ј (Gcsfr promoter from Ϫ222 to Ϫ37). The RT-qPCR results were calculated with the ⌬⌬C t method and presented as fold of enrichment relative to control rabbit IgG.
Chromatin Regulator Inhibitor Treatment of Leukemia Cells-EZH2 and G9A inhibitors were obtained from SGC. EZH2 inhibitor SGC code UNC1999 (Ei) inhibits EZH2 with an IC 50 of 2 nM, with Ͼ22-fold higher IC 50 for EZH1 and Ͼ1000fold higher IC 50 for other histone methyltransferases (HMTs). EZH2 inhibitor SGC code GSK343 (Ei2) inhibits EZH2 with an IC 50 of 4 nM, Ͼ60-fold higher IC 50 for EZH1 and Ͼ1000-fold higher IC 50 for other HMTs. G9A inhibitor SGC code UNC0642 (Gi) inhibits G9a with an IC 50 Ͻ15 nM, and Ͼ100fold higher IC 50 for 13 other HMTs. G9A inhibitor SGC code A-366 (Gi2) inhibits G9a with an IC 50 of 3 nM, and Ͼ100-fold higher IC 50 over other HMTs. All the above inhibitors were added to cells at 5 M every 24 h. Decitabine (Tocris, catalog number 2624) was used to deplete DNMT1 and added to cells at 0.5 M on day 1 and 0.2 M on day 2. Cells treated were patientderived leukemia cell lines: Kasumi1 containing RUNX1-ETO, OCI-AML2 containing DNMT3A, MLL, and FLT3 mutations, and OCI-AML3 containing DNMT3A, NPM1, and NRAS mutations.
Analysis of Public ChIP-Seq Data-The R programming environment (47) was used to analyze the chip-seq data of Wilson et al. (17) . A script was written that identified all genes that had Pu.1 and RUNX1 binding sites within 50 base pairs of each other. Peak to gene mapping was per the original publication (17) . Expression levels of these genes where then compared across various experimental conditions.
Microarray Gene Expression Data Analysis-Quality controlled data (GSE24006 (24), GSE13125 (25)) were downloaded from Gene Expression Omnibus (GEO) datasets or TCGA. Heat maps were generated using ArrayStar version 3.0 (DNASTAR).
Functional Ontology Enrichment Analysis-For gene tissue expression annotation gene lists were uploaded into DAVID (26) . Enrichment analysis involves matching an "omics" data set to terms in functional ontologies, providing a ranked representation of ontologies that are most saturated or "enriched" with the input data. Statistical relevance of the found ontology matches was calculated as p value, or a probability of a match to occur by chance, given the size of the database.
RESULTS
Runx1 Deficiency Switched Pu.1 Interaction from Coactivators to Corepressors-Primary AML cells, including cells containing mutations or translocations of RUNX1, express very high levels of master drivers of hematopoietic lineage differentiation compared with non-malignant hematopoietic stem and progenitor cells (e.g. PU.1 and CEBPA) ( Fig. 1) (20, (27) (28) (29) . Yet, the AML cells are differentiation arrested by morphology and demonstrate epigenetic repression of key differentiation target genes of these same transcription factors (20, (27) (28) (29) .
One possible cause of this epigenetic repression is altered coregulator recruitment to master differentiation driving transcription factors, caused by leukemia-initiating events such as RUNX1 deficiency. Proteins that coimmunoprecipitated with endogenous Pu.1 from primary bone marrow and spleen cells from Runx1 haploinsufficient (Runx1 ϩ/Ϫ ) and wild-type littermate control mice were therefore evaluated by Western blot for components representative of different coactivator and corepressor families (2) . In wild-type cells, multiple coactivators (Smarca4, Ncoa5, Ruvbl1, and Ruvbl2) were pulled down with Pu.1. Runx1 deficiency produced a striking switch to Pu.1 interaction with multiple corepressors (Chd4, Rest, Lsd1, Rbbp4, Mbd2, Smarca5, and Phb2) (Fig. 2) .
To examine the time course of Pu.1 corepressor/coactivator interactions during progressive macrophage maturation, we utilized a cell line model of Pu.1-driven macrophage differenti-ation (PUER: Pu.1 knock-out hematopoietic precursor cells retrovirally transduced to express Pu.1 fused to the estrogen receptor). The addition of tamoxifen to these cells translocates Pu.1 into the nucleus and triggers terminal macrophage differentiation (20, 23, 30) . Runx1 deficiency was produced in this model by lentiviral transduction with shRNA (PUER shRunx1). PUER cells transduced with pLenti6 empty vector were used as controls (PUER control) (20) . Pu.1 was immunoprecipitated from control and Runx1-deficient cells at various time points after Pu.1 introduction into the nucleus by OHT ( Fig. 3) . At the earliest time point after Pu.1 introduction into the nucleus (5 min) in control cells, there was substantial coactivator (Smarca4 and Ncoa5) interaction with Pu.1 (Fig. 3 ). However, in shRunx1 cells, there was no detectable Smarca4 and substantially less Ncoa5 interaction with Pu.1 (Fig. 3) , instead, there was substantially increased recruitment of corepressors (Sin3a, Chd4, Dnmt1, Kdm1a/Lsd1, Eto2, Hdac1, and Hdac2) to Pu.1 at all time points (Fig. 3) . As previously observed, progressive maturation of PUER shRunx1 cells was impeded and these cells demonstrated a proliferative advantage over empty vector controls ( Fig. 3) (20) . Thus, Runx1 regulation of Pu.1 corepressor/ coactivator exchange is immediate and persistent during Pu.1driven progressive maturation.
Then, to more comprehensively catalogue the corepressor and coactivator interactions of Pu.1 in the wild-type and Runx1-deficient context with a scope not possible by Western blot, proteins that co-immunoprecipitated with Pu.1 from PUER control and shRunx1 cells were resolved by one-dimensional SDS-PAGE then analyzed by LC-MS/MS. In three independent experiments, the NuAT and Baf families of coactivators reproducibly coimmunoprecipitated with Pu.1 in control cells. Runx1 deficiency produced a conspicuous and significant FIGURE 1. A, primary AML cells, such as leukemia stem cells (LSC) and leukemia progenitor cells (LPC), express high levels of master differentiation-driven transcription factors CEBPA (granulocyte differentiation) and PU.1 (macrophage differentiation) compared with normal bone marrow hematopoietic stem cells (HSC), multipotent progenitors (MPP), granulocyte monocyte progenitors (GMP), and megakaryocyte erythroid progenitors (MEP). Shown for reference are expression levels also of GATA1 (master driver of erythroid differentiation). Raw data were downloaded from Geo Datasets GSE24006. Gene expression microarray data Affymetrix U133 Plus 2.0 microarrays were from cell populations purified by fluorescence-activated cell sorting: AML LSC (Lin-CD34ϩCD38-CD90-, n ϭ 7), AML PC (Lin-CD34ϩCD38ϩ, n ϭ 7), AML Blasts (Lin-CD34-), normal hematopoietic stem cells (Lin-CD34ϩCD38-CD90ϩCD45RA-; n ϭ 4), multipotent progenitors (Lin-CD34ϩCD38-CD90-CD45RA-; n ϭ 4), common myeloid progenitors Lin-CD34ϩCD38ϩCD123ϩCD45RA-; n ϭ 4), granulocytemonocyte progenitors (Lin-CD34ϩCD38ϩCD123ϩCD45RAϩ; n ϭ 4), and megakaryocyte-erthythrocyte progenitors (Lin-CD34ϩCD38ϩCD123-CD45RA-; n ϭ 4). B, primary acute myeloid leukemia cells representative of the morphologic/genetic spectrum of disease (TCGA, n ϭ 179) express high levels of key hematopoietic lineage specifying transcription factors (TF) (TCGA RNA Seq). For comparison purposes, expression levels of a key hematopoietic stem cell (HSC) driving TF and embryonic stem cell (ESC) TF are shown. M0, minimally differentiated; M1, without maturation; M2, with maturation; M3, promyelocytic; M4, myelomonocytic; M5, monocytic; M6, erythroid; M7, megakaryocytic. MAY 23, 2014 • VOLUME 289 • NUMBER 21 JOURNAL OF BIOLOGICAL CHEMISTRY 14885 switch to Pu.1 interaction with Dnmt1 and the Sin3A, Nurd, CoRest, and B-Wich corepressor families ( Figs. 4 and 5 ). Interestingly, two chromatin remodeling protein families implicated in leukemogenesis, the Trithorax (Mll) family associated with activation and the Polycomb families associated with repression (Polycomb Repressor Complex 1 and 2, PRC1 and PRC2), did not interact with Pu.1 in either control or Runx1-deficient cells (Fig. 5 ). Neither did Dnmt3a, another chromatin modifying enzyme that is a PRC2 component and is frequently genetically inactivated in myeloid neoplasms ( Fig. 5) (31, 32) . These immunoprecipitation LC-MS/MS results were verified by Western blot (Fig. 3) .
RUNX1 and PU.1 Cooperation
As an additional indication that these coactivators and corepressors are relevant to normal and malignant human hematopoiesis, the majority were expressed at similar high levels in primary AML cells (RNA sequencing, normal cytogenetics AML, TCGA, n ϭ 99) (Fig. 6, A and B) , and Runx1 deficiency per se did not alter the overall expression of these coactivators and corepressors, because expression was similar in primary AML cells containing wild-type or mutated RUNX1 (Fig. 6, A and B) .
Runx1 Deficiency Did Not Decrease Pu.1 Binding to a Key Target Gene, but Impaired the Pu.1-driven Shift from Histone Repression to Histone Activation Marks-Lists of genes that are bound by Pu.1 and Runx1 together in proximity (within 50 bp), and lists of genes that were bound by Pu.1 but without Runx1, were generated from ChIP-Seq analyses of Runx1 and Pu.1 binding in murine hematopoietic precursor cells (17) . The most significant tissue expression association of Runx1-Pu.1 co-bound genes in DAVID gene ontology analyses was with macrophages, a Pu.1-dependent hematopoietic lineage. In contrast, Pu.1 binding without Runx1 had tissue expression associations with non-hematologic tissues (Table 1) . Accordingly, the functional consequences of disrupted Pu.1 corepressor/coactivator exchange were measured at a key macrophage differentiation gene (Mcsfr) versus a key granulocyte differentiation gene (Gcsfr) in PUER control and shRunx1 cells. By chromatin immunoprecipitation, there was a severe decrease in Runx1 binding to the Mcsfr and Gcsfr promoters in Runx1-deficient compared with control cells (Fig. 7A ). Pu.1 binding to Mcsfr and Gcsfr promoters, however, was not decreased by Runx1 deficiency (Fig. 7A) . In control cells, 12 and 24 h after addition of OHT to trigger Pu.1 nuclear entry, there was a substantial increase from baseline in the histone activation mark H3K4Me2 at the Mcsfr promoter but not the Gcsfr promoter in control cells (Fig. 7B) . In contrast, in Runx1-deficient cells, there was a 7-fold lower level of this activation mark at the Mcsfr promoter (relevant to the actions of the Lsd1/Kdm1a containing Nurd corepressor complex), both at baseline and after Pu.1 translocation into the nucleus. Activation mark levels were also lower at the Gcsfr promoter in Runx1-deficient compared with control cells (Fig. 7B) . The repression mark H3K9Me2 demonstrated the opposite pattern: it was higher in Runx1-deficient compared with control cells at both promoters at all time points before and after Pu.1 translocation into the nucleus (Fig. 7C ). As expected, Runx1 deficiency impeded macrophage differentiation ( Fig. 3) (20) .
DNMT1 Inhibition, but Not Polycomb Inhibition, in RUNX1translocated Leukemia Cells Restored Terminal Differentiation-
A non-cytotoxic inhibitor is available for DNMT1, a chro-matin modifying enzyme recruited to Pu.1 in the Runx1deficient cells. In patient-derived RUNX1-ETO leukemia cells (Kasumi1), this inhibitor (decitabine) activated MCSFR, up-regulated protein levels of the cyclin-dependent kinase inhibitor p27/CDKN1B that mediates cell cycle exit by differentiation, and decreased proliferation (Fig. 8, A-C) . Noncytotoxic inhibitors are also available for Polycomb corepressors (EZH2 and G9a) that were not recruited to Pu.1 in Runx1-deficient cells (Structural Genomics Consortium). In contrast, to the results with the DNMT1 inhibitor, the EZH2 and G9a inhibitors did not decrease MYC protein or was IPed from PUER controls (empty vector pLenti6) and PUER shRunx1 cells at various time points after Pu.1 introduction into the nucleus by OHT. The co-IP was analyzed by Western blot (WB). A, coactivator (Smarca4 and Ncoa5) and corepressor (Sin3a, Chd4, Dnmt1, Lsd1, Eto2, Hdac1, and Hdac2) abundance in the Pu.1 co-IP during progressive macrophage differentiation of PUER controls and PUER shRunx1 cells. Bottom panels show Western analysis of IPed Pu.1 and co-IPed Runx1. Histograms are results of densitometric quantification of co-IPed bands relative to the intensity of IPed Pu.1 bands. B, Pu.1 translocation from the cytoplasm into the nucleus with addition of OHT. C, morphology of PUER control and PUER shRunx1 cells before and 24 h after addition of OHT (macrophage differentiation). Giemsa-stained cytospin preparations of cells at ϫ200 (microscope model Leica DMR, Leica Microsystems, IL). Images were captured using the attached CRI Nuance NzMSI-FX multispectral imaging system with Nuance software version 2.8 (NuanceCRI). These results were reproduced in three independent experiments. MAY 23, 2014 • VOLUME 289 • NUMBER 21
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decrease proliferation of RUNX1-ETO leukemia cells (Fig. 8 , D-F).
Polycomb (EZH2 and G9a) Inhibition Increased Differentiation and Decreased Proliferation of Leukemia Cells Containing DNMT3A, MLL, FLT3, and NPM1 Alterations but Wild-type RUNX1-The EZH2 and G9a inhibitors did, however, decrease proliferation, decrease MYC protein, and increase differentiation of leukemia cells (OCI-AML2 and OCI-AML3) that do not contain RUNX1 alterations (OCI-AML2 contains DNMT3A, MLL, and FLT3 mutations and OCI-AML3 contains DNMT3A, NPM1, and NRAS mutations)( Fig. 9 ).
DISCUSSION
High expression in leukemia cells of master differentiation driving transcription factors PU.1 and CEBPA yet epigenetic repression of differentiation target genes suggests that coregulator recruitment to the differentiation drivers could be altered (20, (27) (28) (29) . In wild-type hematopoietic cells, Pu.1 interacted with coactivators of the NuAT and Baf families. Deficiency of Runx1, a frequent leukemia-initiating event, disrupted this cooperative corepressor/coactivator exchange to produce a striking switch to Pu.1 interaction with corepressors Dnmt1, Prmt5, Sin3A, Nurd, CoRest, and B-Wich. Such altered coregulator interaction likely contributes to the global decrease in histone activation and increase in histone repression marks which is observed in RUNX1-deficient primary leukemia cells (20, 33) . A fraction of the hundreds of transcription factors expressed in cells are master drivers of lineage specification and differentiation. Leukemia cells express high levels of such master differentiation drivers, and these continue to bind the promoters and enhancers of the differentiation genes (17) . Taken together with the dynamic nature of corepressor/coactivator interchange (3, 20) , this suggests that antagonizing corepressors that are aberrantly recruited to the differentiation drivers may restore differentiation gene expression. Accordingly, depletion of DNMT1 by genetic methods (34, 35) or by repurposing of the clinically available drug decitabine, restored expression of late differentiation genes and progressive maturation even in p53/ p16-null leukemia cells resistant to standard apoptosis-based therapy (28, 29) . Genetic or pharmacologic suppression of KDM1A (LSD1), a component of the NURD corepressor complex aberrantly recruited to Pu.1 in Runx1-deficient cells, also induced terminal maturation in murine leukemia models (36, 37) . Similarly, inhibition of HDAC1 and HDAC2, chromatinmodifying enzyme components of the SIN3A and NURD corepressor families aberrantly recruited to Pu.1 in Runx1-deficient cells, also restored expression of epigenetically repressed differentiation genes and terminal maturation (38 -41) . By extension, SMARCA5, an ATP-dependent chromatin remodeler recruited to Pu.1 in Runx1-deficient cells and which is overexpressed in primary AML (42) , and PRMT5, an arginine methyltransferase recruited to Pu.1 in Runx1-deficient cells, are pre-sumably suitable molecular targets for therapies aiming to induce cell cycle exit by terminal differentiation. It is worth reiterating that such cell cycle exits do not require master apoptosis regulators such as p53 and p16/CDKN2A that are recurrently genetically deleted in leukemia cells, and which are needed for the actions of standard cytotoxic treatments (29, 43) .
Another suggestion of these results is that genetic inactivation of specific coactivators that mediate the actions of differentiation driving transcription factors could be another method (besides RUNX1 inactivation etc.) by which leukemia cells impede activation of proliferation terminating differentiation genes: SMARCB1 is a chromatin-modifying enzyme component of the BAF coacti- vator complex that was recruited to PU.1/RUNX1: SMARCB1 is deleted in 36% of chronic myeloid leukemia cases transforming into blast crisis (secondary AML), a transformation defined by impairment of progressive myeloid maturation (44) . Similarly, SMARCD3, another BAF coactivator component, is frequently homo-or heterozygously deleted (13%) in AML (TCGA).
Polycomb family members that mediate transcription repression did not interact with Pu.1. Accordingly, Polycomb inhibitors (EZH2 and G9a inhibitors) did not induce differentiation in leukemia cells containing translocated RUNX1. However, these Polycomb inhibitors did induce differentiation in leukemia cells with genetic alterations other than in RUNX1. One possible explanation for this observation is that other leukemogenic genetic events may cause EZH2 or G9a to be aberrantly recruited to differentiation-driven transcription factors. Another speculation is suggested by the conserved role of polycomb repressor complex 2 (PRC2) in repressing lineage programs: inactivating mutations or deletions of PRC2 components are frequent in leukemia (e.g. EZH2 or ASXL1 mutation or deletion), events associated with derepression of particular lineage programs, presumably because of MYC up-regulation and vigorous proliferation that accompanies this (45, 46) . For example, FIGURE 7 . Runx1 deficiency does not decrease Pu.1 binding to the Mcsfr promoter, but impairs the Pu.1-driven shift from histone repression to histone activation marks at this locus. For comparison, a key granulocyte differentiation gene, Gcsfr, was also analyzed. A, Runx1 deficiency severely decreased Runx1 binding but did not decrease Pu.1 binding to the Mcsfr promoter. Chromatin immunoprecipitation (IP) with anti-Pu.1 and anti-Runx1 was 12 h after addition of OHT to trigger Pu.1 nuclear entry into PUER Empty Vector (control) and PUER shRunx1 (Runx-deficient) cells. Co-immunoprecipitated promoter regions were quantified by RT-qPCR, presented as fold-enrichment relative to control rabbit IgG. Mean Ϯ S.D., **, p Ͻ 0.01, Student's t test. Experiments were performed in triplicate. B, in Runx1-deficient cells, the histone activation mark H3K4Me2 was decreased at Mcsfr and Gcsfr promoters at various time points before and after Pu.1 introduction into the nucleus compared with control cells. Chromatin immunoprecipitation was with anti-H3K4Me2. Analysis as indicated in panel A. C, in contrast, the histone repression mark H3K9Me2 was increased in Runx1-deficient cells. Chromatin immunoprecipitation was with anti-H3K9Me2. Analysis as indicated in panel A.
TABLE 1 Top 5 tissue expression associations of genes which are bound by both Pu.1 with Runx1 in proximity (within 50 bp of each other) compared to genes bound by Pu.1 but without Runx1 co-binding
Pu.1 and Runx1 binding peak to gene mapping as described by Wilson et al. (17) . Gene ontology analysis was done using DAVID (26) (UP_Tissue). EZH2, inactivation is linked with up-regulation of the megakaryocyte specifying transcription factor FLI1, high platelet counts, and acute megakaryocytic leukemia; ASXL1 inactivation is linked with up-regulation of the macrophage specifying transcription factor PU.1 and chronic myelomonocytic leukemia (45) . Leukemia cells lineage specified in this way presumably also contain genetic/epigenetic alterations that efficiently obstruct progressive maturation within the de-repressed lineage paths. Alternative differentiation paths may not be as vigorously obstructed, explaining why inhibiting other PRC2 components may release these alternative differentiation directions (45) . The mode of cooperation demonstrated by RUNX1/PU.1, combining to exclude corepressors and recruit coactivators instead, could also mediate RUNX1 synergy with other lineage specifying transcription factors (e.g. CEBPA, FLI1, etc.), and explains the repression by epigenetic means of multiple key late differentiation genes in leukemia cells despite high-level expression of the lineage specifying transcription factors that usually activate these genes. The corepressors aberrantly recruited to differentiation drivers as a consequence of genetic events such as RUNX1 inactivation are specific and drugable targets for therapy that aims to produce leukemia cell cycle exit by differentiation, as an alternative to frequently ineffective apoptosis-based therapy.
Tissue
